News By Tag * Reimbursement * Payer * Tools * Hta * Stakeholder * Pharmaceutical * Drug * Patient * Clinical * Healthcare * More Tags... Industry News News By Location Country(s) Industry News
|  New Market Research Report: Reimbursement in Europe and Indication-Specific PricingNew Pharmaceuticals market report from Business Insights: "Reimbursement in Europe and Indication-Specific Pricing"
By: Fast Market Research, Inc. Scope * Understand the key determinants of success in gaining a higher price in a subsequent indication. * Assess pricing and reimbursement systems in major European markets. * Evaluate developments to pricing and market access systems in the UK, Germany, France, Italy, and Spain. * Develop an understanding of how payers value pharmaceutical products. * Learn how international price referencing is being applied across EU markets. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Report Highlights When seeking a higher price for an additional indication, in an ideal case, the product will offer superior clinical and economic value, the additional indication will have a small, geographically concentrated population, and the product will be delivered in specialized clinics or hospitals only. Barriers to dual pricing may include regulatory issues, and lack of differentiation at supply chain and prescriber levels. Germany, the UK, and France among others are changing pricing and reimbursement systems, in efforts to contain healthcare spending. Most notably, free pricing in Germany is to become much more constrained. Reasons to Get this Report * What changes are occurring in pricing and reimbursement in major markets? * Which key stakeholders control the pricing and market access systems in major markets? * What are the potential barriers to dual pricing initiatives? * How can drug developers deal with value-assessment and pricing methodologies in major markets? * What factors need to be considered when seeking a higher price in an additional approved indication? Companies Mentioned in this Report: ArcelorMittal, Aviva Plc, Hutchison 3G UK Limited, IMS Health, Royal KPN N.V., Schindler Holding Ltd., Sistema JSFC Partial Table of Contents: EXECUTIVE SUMMARY - Introduction and background - Pricing methodologies and analysis - Value assessment of pharmaceuticals - Pricing and market access systems in major markets - Evolving pricing and market access systems in key EU markets - Scenario development for indication-specific, value-based pricing Introduction and background - Summary - Introduction - Defining the key question - Method of analysis - Assessing value and reward - Differential pricing based on patient populations - How to use this report - Brand managers and those involved in licensing - Pricing and Reimbursement managers - Healthcare investors and analysts Pricing methodologies and analysis - Summary - Tools to control pharmaceutical pricing - Understanding variation in drug prices - Realities of a list price - Prices at different points in the supply chain - International reference pricing (IRP) - Selection of countries - Usage of IRP and linkages between countries - Future trends in IRP usage - Reference pricing within therapeutic groups (TRP) - Implications of therapeutic reference pricing Value assessment of pharmaceuticals - Summary - Introduction - Components of value - Problems in assessing value at launch - Technology assessment and appraisal - Health technology assessment (HTA) - HTA cooperation in Europe - Key principles for an HTA assessment - Structure of HTA programs - Methods of a health technology appraisal - Processes for conducting an HTA - Use of HTAs in decision making Pricing and market access systems in major markets - Summary - Introduction - Making pricing and market access decisions with uncertain evidence - Payer environment in the US and Europe - France - Pricing and reimbursement decisions in France are taken on a step by step basis - Pricing and improvement in medical benefit (ASMR) - Reimbursement and medical benefit rating (SMR) - Payer management tools - UK - Stakeholder landscape - Pricing: Pharmaceutical Price Regulation Scheme versus value-based pricing - Reimbursement - Payer management tools - Germany - Stakeholder landscape - Pricing of pharmaceuticals - Reimbursement - Payer management tools - Issues surrounding parallel trade - Italy - Stakeholder landscape - Pricing of pharmaceuticals - Reimbursement - Payer management tools - Spain - Stakeholder landscape - Pricing of pharmaceuticals - Reimbursement - Payer management tools Evolving pricing and market access systems in key EU markets - Introduction - Changing UK pricing landscape - Rise of GP consortia and local budget management - Introduction of value-based pricing - Payment by results - New funding mechanisms for cancer - Increasing power to patients - Expansion of Healthcare Resource Groups - Key trends and implications - Budget impact and pricing changes in France - Cost containment - Influence of ARS on hospital purchasing and pricing - Developments within regional oncology networks - HTA proliferation - Key trends and implications - End of free-pricing in Germany - AMNOG legislation - Increasing use of HTAs in price setting - Conservative price forecasts - Growing fixed price restrictions - New payment methods - Key trends and implications Scenario development for indication-specific, value-based pricing - Summary - Introduction - Approach to developing recommendations - Defining the value proposition - Best case: superior clinical and economic evidence - Base case: superior clinical evidence only - Worst case: superior economic evidence only - Defining case-specific realities - Relatedness of new indication - Number of existing indications - Setting of care - Disease importance and public profile - Size of patient population - Geographical distribution of patients in new indication - Market dominance of drug in earlier indications - Types of barriers Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Insights Business Insights appreciate the importance of accurate, up-to-date incisive market and company analysis and their aim therefore is to provide a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors. By working in association with so many experts they are able to provide clients with more incisive market analysis specific to the client's industry sector. No other market analysis company provides such focused and trusted market analysis, across such a wide range of industry sectors. View more research from Business Insights at http://www.fastmr.com/ # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number